Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882231 · ClinicalTrials.gov registry record · NA
Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT01882231 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT01882231, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of these studies is to use changes in 3 Tesla MRI measurements of tumor protein content, cell density, and microvessel perfusion, obtained before and after a single cycle of NAC, to predict eventual tumor response observed at the conclusion of NAC, within patients with osteosarcoma or Ewing Sarcoma.
Interventions
- OTHER DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-04-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01882231
The ClinicalTrials.gov registry entry for NCT01882231 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI is the first listed.
NCT01882231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01882231 about?
NCT01882231 is a clinical study titled "Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma". The objective of these studies is to use changes in 3 Tesla MRI measurements of tumor protein content, cell density, and microvessel perfusion, obtained before and after a single cycle of NAC, to predict eventual tumor response observed at the conclusion of NAC, within patients with osteosarcoma or ...
What is the current status of trial NCT01882231?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2013-03. Estimated completion is 2016-04-25.
What interventions are being tested in trial NCT01882231?
The interventions under investigation include: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI (OTHER).
Who is sponsoring clinical trial NCT01882231?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.